MRD對(duì)評(píng)估AML-M2治療效果及預(yù)后作用的探討.pdf

1、蘇州大學(xué)碩士學(xué)位論文MRD對(duì)評(píng)估AML-M2治療效果及預(yù)后作用的探討姓名：陳黎申請(qǐng)學(xué)位級(jí)別：碩士專業(yè)：流行病與衛(wèi)生統(tǒng)計(jì)學(xué)指導(dǎo)教師：滕國(guó)興2010-103 Assessment of response to therapy and prognosis by monitoring of minimal residual disease in acute myeloid leukemia MAssessment of re

2、sponse to therapy and prognosis by monitoring of minimal residual disease in acute myeloid leukemia M2 [Abstract]: [Abstract]: Objective ： To find out the relationship of minimal residual disease(MRD) and

3、cytogenetic characteristics in adult acute myeloid leukemia(AML) M2. Methods ： Immunophenotyping and the level of MRD using eukemia-associated immunophenotypic (LAIP)was analysed by multiparametric flow cytomet

4、ry(MFC) in 117 adult M2-AML. Results ： Based on cytogenetic characteristics , 3 different prognostic categories were identified. The level of MRD has no difference in 3 different prognostic categories. In this group

5、 MRD levels were defined as high ( ≥5x10 -3) and low (<5x10 -3) level one year.The incidence of relapse were 29.4% and 8.8%, in the 2 groups, respectively, with a higher incidence among patients who were

6、in MRD high level group than in those who were in MRD low group (P< 0.05). Conclusion： Immunophenotypical evaluation of MRD in M2-AML can be reliably used to assess early response to treatment and predict rela